- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00942266
Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment
A Randomized Phase II Study of Two Dose-Levels of Vorinostat in Combination With 5-FU and Leucovorin in Patients With Refractory Metastatic Colorectal Cancer
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
New York
-
Buffalo, New York, Forente stater, 14263
- Roswell Park Cancer Institute
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion
- Patients must have histologically or cytologically confirmed colorectal adenocarcinoma that is metastatic and which has failed standard treatment or for which no standard treatment is available
- Patients should have fluoropyrimidine-refractory disease; radiographic evidence of progression within 4 weeks from the last dose of a fluoropyrimidine-based regimen (at least 6 weeks of fluoropyrimidine-based treatment)
- Patients should have received and progressed on (or proved to be intolerant to) oxaliplatin and irinotecan; progression within 6 months from oxaliplatin-based therapy or irinotecan-based therapy is acceptable for eligibility
- Patients with KRAS wild-type or unknown KRAS status tumors should have progressed on or within 6 months from last cetuximab or panitumumab-based therapy; no prior cetuximab therapy is required for KRAS mutant tumors
- ECOG performance status =< 2
- Life expectancy >= 12 weeks
- Ability to understand and the willingness to sign a written informed consent document
- Ability to swallow pills
- Absolute neutrophil count >= 1,500/uL
- Platelets >= 100,000/uL
- Total bilirubin =< institutional upper limit of normal
- AST(SGOT)/ALT(SGPT) =< 3 x institutional upper limit of normal in the absence of metastatic disease to the liver and =< 5 x institutional upper limit of normal in the setting of metastatic disease to the liver
- Creatinine =< 1.5 x institutional upper limit of normal
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation
- Males undergoing study treatment should also agree to adequate measures of contraception (partner contraception and use of condoms or abstinence, or vasectomy)
Exclusion
- Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from significant adverse events due to agents administered more than 3 weeks earlier
- Patients may not be receiving any other investigational agents
- Patients with known brain metastases should be excluded from this clinical trial
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat or other agents used in study
- Greater than Grade 2 neuropathy as defined by CTCAE version 3.0
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Baseline EKG with QTc prolongation that is grade 2 or higher by CTCAE version 3.0
- Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with vorinostat
- Patients should not have taken valproic acid or other histone deacetylase inhibitors, for at least 4 weeks prior to enrollment
- Patients with known HIV infection or known active viral hepatitis
- Prior treatment with vorinostat
- Other non-study medications known to increase the QTc interval
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Arm I
Patients receive low-dose oral vorinostat once daily on days 1-3, leucovorin calcium IV over 2 hours on day 2, and fluorouracil IV over 46 hours on days 2 and 3. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
|
Gitt IV
Andre navn:
Gitt IV
Andre navn:
Korrelativ studie
Andre navn:
Gis muntlig
Andre navn:
|
Eksperimentell: Arm II
Patients receive high-dose oral vorinostat once daily on days 1-3 and leucovorin calcium and fluorouracil as in arm I. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
|
Gitt IV
Andre navn:
Gitt IV
Andre navn:
Korrelativ studie
Andre navn:
Gis muntlig
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Disease Control Rate (Stable Disease or Objective Response)
Tidsramme: At 2 months
|
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. |
At 2 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Median Progression-free Survival
Tidsramme: Every 8 weeks, up to 100 weeks.
|
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
|
Every 8 weeks, up to 100 weeks.
|
Response Rate
Tidsramme: Every 8 weeks; up to 100 weeks.
|
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. |
Every 8 weeks; up to 100 weeks.
|
Toxicity
Tidsramme: Daily
|
Number of participants with an adverse event. Please refer to the adverse event reporting for more detail. |
Daily
|
Overall Survival
Tidsramme: Every 12 weeks
|
Every 12 weeks
|
|
Vorinostat Pharmacokinetics
Tidsramme: day 2 (cycle 1)
|
Blood samples (5 ml of blood each) will be collected in red-top vacutainers (no anticoagulant) at 0 (pre- vorinostat), 0.5, 1, 2, 3, 4, 6, and 8 hours after the vorinostat dose on the first day of 5-FU infusion on cycle 1 (day 2 of cycle 1).
Mean area under the curve is presented with 95% CI.
|
day 2 (cycle 1)
|
Fluorouracil Steady-state Pharmacokinetics
Tidsramme: Day 1
|
Blood samples will be collected for determination of plasma 5-FU steady state concentration at 6 hours after start of 5-FU continuous infusion.
The mean per treatment arm are presented.
|
Day 1
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Wen Wee MA, MD, Roswell Park Cancer Institute
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Sykdommer i fordøyelsessystemet
- Patologiske prosesser
- Neoplasmer etter histologisk type
- Neoplasmer
- Neoplasmer etter nettsted
- Karsinom
- Neoplasmer, kjertel og epitel
- Sykdomsattributter
- Gastrointestinale neoplasmer
- Neoplasmer i fordøyelsessystemet
- Gastrointestinale sykdommer
- Kolonsykdommer
- Tarmsykdommer
- Intestinale neoplasmer
- Rektale sykdommer
- Kolorektale neoplasmer
- Tilbakefall
- Adenokarsinom
- Rektale neoplasmer
- Kolon neoplasmer
- Fysiologiske effekter av legemidler
- Molekylære mekanismer for farmakologisk virkning
- Enzymhemmere
- Antimetabolitter, antineoplastisk
- Antimetabolitter
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Beskyttende agenter
- Mikronæringsstoffer
- Vitaminer
- Bone Density Conservation Agents
- Kalsiumregulerende hormoner og midler
- Motgift
- Vitamin B kompleks
- Histon deacetylase-hemmere
- Fluorouracil
- Leucovorin
- Kalsium
- Levoleucovorin
- Kalsium, kosthold
- Vorinostat
Andre studie-ID-numre
- I 142808
- NCI-2009-01523
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Trinn IV tykktarmskreft
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Har ikke rekruttert ennåMetastatisk kolorektal adenokarsinom | Metastatisk tykktarmsadenokarsinom | Metastatisk rektal adenokarsinom | Trinn IV tykktarmskreft AJCC v8 | Trinn IV tykktarmskreft AJCC v8 | Stage IV endetarmskreft AJCC v8Forente stater
-
City of Hope Medical CenterNational Cancer Institute (NCI)RekrutteringMetastatisk kolorektal adenokarsinom | Metastatisk tykktarmsadenokarsinom | Metastatisk rektal adenokarsinom | Trinn IV tykktarmskreft AJCC v8 | Trinn IV tykktarmskreft AJCC v8 | Stage IV endetarmskreft AJCC v8 | Metastatisk mikrosatellitt stabilt kolorektalt karsinomForente stater
-
National Cancer Institute (NCI)RekrutteringMetastatisk tykktarmsadenokarsinom | Metastatisk rektal adenokarsinom | Trinn III tykktarmskreft AJCC v8 | Stadium III endetarmskreft AJCC v8 | Trinn IV tykktarmskreft AJCC v8 | Stage IV endetarmskreft AJCC v8 | Ikke-opererbart tykktarmsadenokarsinom | Uopererbart rektal adenokarsinomForente stater, Puerto Rico
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeMetastatisk malignt fast neoplasma | Trinn IV tykktarmskreft AJCC v8 | Stage IV endetarmskreft AJCC v8 | Stage IVA tykktarmskreft AJCC v8 | Stage IVA endetarmskreft AJCC v8 | Stage IVB tykktarmskreft AJCC v8 | Stadium IVB endetarmskreft AJCC v8 | Rektal adenokarsinom | Colon adenokarsinom | Høyfrekvent mikrosatellitt-ustabilitet og andre forholdForente stater
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)FullførtTrinn IV tykktarmskreft AJCC v7 | Stage IVA kolorektal kreft AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Rektal adenokarsinom | Colon adenokarsinom | Trinn III tykktarmskreft AJCC v7 | Trinn IIIA tykktarmskreft AJCC v7 | Trinn IIIB tykktarmskreft AJCC v7 | Stage IIIC tykktarmskreft AJCC v7Forente stater
-
Mayo ClinicFullførtMetastatisk kolorektal adenokarsinom | Metastatisk tykktarmsadenokarsinom | Metastatisk kolorektalt karsinom | Metastatisk rektal adenokarsinom | Trinn IV tykktarmskreft AJCC v8 | Stage IVA tykktarmskreft AJCC v8 | Stage IVB tykktarmskreft AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatisk mikrosatellitt... og andre forholdForente stater
-
National Cancer Institute (NCI)AvsluttetKolorektal karsinom | Metastatisk tykktarmsadenokarsinom | Metastatisk rektal adenokarsinom | Trinn III tykktarmskreft AJCC v8 | Stadium III endetarmskreft AJCC v8 | Trinn IIIA tykktarmskreft AJCC v8 | Stadium IIIA endetarmskreft AJCC v8 | Trinn IIIB tykktarmskreft AJCC v8 | Stadium IIIB endetarmskreft... og andre forholdForente stater
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeTilbakevendende tykktarmskarsinom | Tilbakevendende rektal karsinom | Rektal adenokarsinom | Colon adenokarsinom | ERBB2 genamplifikasjon | Trinn III tykktarmskreft AJCC v7 | Stage III rektal kreft AJCC v7 | Trinn IIIA tykktarmskreft AJCC v7 | Stadium IIIA endetarmskreft AJCC v7 | Trinn IIIB tykktarmskreft... og andre forholdForente stater, Puerto Rico
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)AvsluttetMetastatisk tykktarmsadenokarsinom | Metastatisk rektal adenokarsinom | Trinn III tykktarmskreft AJCC v8 | Stadium III endetarmskreft AJCC v8 | Trinn IIIA tykktarmskreft AJCC v8 | Stadium IIIA endetarmskreft AJCC v8 | Trinn IIIB tykktarmskreft AJCC v8 | Stadium IIIB endetarmskreft AJCC v8 | Trinn IIIC tykktarmskreft... og andre forholdForente stater
-
M.D. Anderson Cancer CenterBristol-Myers Squibb; Syntrix Biosystems, Inc.RekrutteringMetastatisk tykktarmsadenokarsinom | Metastatisk kolorektalt karsinom | Metastatisk rektal adenokarsinom | Trinn III tykktarmskreft AJCC v8 | Stadium III endetarmskreft AJCC v8 | Trinn IIIA tykktarmskreft AJCC v8 | Stadium IIIA endetarmskreft AJCC v8 | Trinn IIIB tykktarmskreft AJCC v8 | Stadium IIIB endetarmskreft... og andre forholdForente stater
Kliniske studier på leukovorin kalsium
-
Aristotle University Of ThessalonikiHellenic Society of HypertensionFullførtHypertensjon | Diabetes | InsulinresistensHellas
-
Shanghai JMT-Bio Inc.CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Ukjent
-
University of Illinois at ChicagoFullført
-
Immunic AGAktiv, ikke rekrutterendeResidiverende-remitterende multippel sklerose (RRMS)Polen, Bulgaria, Romania, Ukraina
-
University Hospital OstravaFullførtGlottisk insuffisiensTsjekkia
-
Cairo UniversityUkjentHvit flekklesjon av tannEgypt
-
Royal Marsden NHS Foundation TrustMerck Serono International SAAvsluttet
-
National Taiwan University HospitalMackay Memorial Hospital; Taipei Veterans General Hospital, Taiwan; National... og andre samarbeidspartnereFullført
-
University of California, San FranciscoNational Cancer Institute (NCI)FullførtHode- og nakkekreftForente stater
-
Yale UniversityFullførtPotensielle applikasjoner for hjertesvikt | Volum overbelastningForente stater